求高手翻译下段英文文献为中文，急，非常感谢！

Question

MGMT promoter methylation in malignant gliomas
The O(6)-methylguanine-DNA methyltransferase (MGMT) gene is located at chromosome 10q26 and codes for a DNA repair enzyme that--if active--can counteract the effects of alkylating chemotherapy. Malignant gliomas often have the MGMT gene inactivated due to aberrant methylation of its promoter region. The assessment of the MGMT promoter methylation status has become of clinical relevance as a molecular marker associated with response to alkylating chemotherapy and prolonged survival of glioblastoma patients. MGMT promoter methylation testing is also on the merge of being used as a marker for patient selection within clinical trials, e.g., the current CENTRIC trial that is specifically focusing on patients with MGMT promoter-methylated glioblastomas. In anaplastic gliomas, MGMT promoter methylation is a favorable prognostic marker independent of the type of therapy, i.e., radio- or chemotherapy. This occurrence might be associated with the high incidence of other prognostically favorable molecular markers in these tumors, such as IDH1 mutation, 1p/19q deletion or yet to be identified novel aberrations. A variety of different methods are being used to assess MGMT promoter methylation in clinical samples, which may give rise to inter-laboratory variations in test results. Immunohistochemical determination of MGMT protein expression has not proven reliable for diagnostic purposes. This brief review article aims to summarize the main aspects of MGMT promoter methylation testing in contemporary neuro-oncology, in particular its value as a clinically useful molecular marker, putting it into the context of other molecular markers of clinical use in gliomas of adult patients.

Answer 1

MGMT在恶性神经胶质瘤的促进者甲基化
The O (6) - methylguanine脱氧核糖核酸methyltransferase (MGMT)基因位于染色体10q26，并且脱氧核糖核酸的代码修理酵素那--如果激活--能抵制烷基化化疗的作用。 恶性神经胶质瘤经常有MGMT基因被撤消的由于它的促进者区域的出轨甲基化。 对MGMT促进者甲基化状态的评估情况临床相关性作为一个分子标志与对烷基化的化疗的反应和glioblastoma患者相关长时期的生存。 MGMT促进者甲基化测试也在合并在临床试验之内的耐心选择的，即，明确地集中于有MGMT促进者甲基化的glioblastomas的患者的当前中心试验使用作为标志。 在整形的神经胶质瘤， MGMT促进者甲基化是种类的疗法，即，收音机或化疗的有利预断标志独立。 这发生也许同其他prognostically有利分子标志联系在一起的高发生在这些肿瘤的，例如IDH1变化， 1p/19q删除或者，是辨认的新颖的变型。 各种各样的不同的方法被用于估计MGMT在临床样品的促进者甲基化，也许提升在测试结果上的多个实验室的变化。 MGMT蛋白质表示的Immunohistochemical决心未证明可靠诊断目的。 这个简要的评论文章在当代神经肿瘤学，特别是它的价值方面打算总结MGMT促进者甲基化测试的主要方面作为一个临床有用的分子标志，放它入其他分子标志上下文在成人患者神经胶质瘤的临床用途。